Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01036841
Other study ID # 2009/653
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date December 2009
Est. completion date April 2010

Study information

Verified date February 2019
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alarm-treatment as well as Desmopressin, a synthetic analogue of human vasopressin, are considered the only evidence-based medicine (EBM) IA treatments in monosymptomatic nocturnal enuresis (MNE). Desmopressin exists in three different formulations for ambulant use: nasal spray, tablet and lyophilisate (MELT) each with differences in bioavailability (spray 2%, tablet 0.2%, MELT 0.5%). There 's insufficient evidence to confirm the actually used bioequivalent doses ( 10µg spray = 120µg MELT= 0.2mg tablet).

Although so frequently used, very few pharmacokinetic and -dynamic data on desmopressin are available for children.

Due to prolonged half life, associated with waterintoxication,the nasal spray has a black box warning from the FDA and is no longer recommended . For some authors oral formulations appear to be a safer alternative. However, based on clinical experience of less response rate with oral formulations, lower biodisponibility is suspected. Adult research confirms low bioavailability of tablets but also show major influences by food-intake and changes in gastro-intestinal motility.

To achieve maximum efficacy, recommendations are to take desmopressin tablet 1 hour before bedtime and 2 hours after meal: this is unrealistic in schoolaged children since there never is 3 hours between evening meal and bedtime.

In 2005 a dose response study demonstrated superior pharmaco-kinetic and dynamic properties for desmopressin Lyophilisate MELT formula.

Since these results implicate superior action of MELT, often a change to MELT is recommended if there is a suboptimal response with tablet: sublingual absorption would eliminate the influence of food-intake.

However, for this statement there's no evidence, since these tests were all conducted in children in fasting condition. Only one clinical study demonstrates bioequivalence for MELT and tablet.

Hypothesis is that desmopressin MELT formulation has a better bioavailability when administered together with meal due to its sublingual absorption.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender All
Age group 6 Years to 16 Years
Eligibility Inclusion Criteria:

- children aged 6-16 years old

- with MNE and nocturnal polyuria

- treated with desmopressin tablet, non or partial responders, for whom change to MELT formulation is indicated according to the international standard guidelines.

Exclusion Criteria:

- history of urologic disease, diurnal urinary incontinence, diabetes insipidus, urinary tract infection, clinically significant disease

- No systemic use of antibiotics, diuretics, other medication that influences urinary concentrating mechanism

- abnormalities of oral mucosa which could influence drugrelease or absorption

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
desmopressin tablet
Administration of desmopressine tablet
desmopressin MELT formulation
Administration of desmopressine MELT formulation

Locations

Country Name City State
Belgium University Hospital Ghent Ghent

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioavailability of desmopressine MELT and tablet when taken with meal. at 1h, 2h and 6h post adminstration
Secondary Pharmacokinetic and pharmacodynamic for desmopressine MELT and tablet. at 1h, 2h, 3h, 6h and 8h post administration
See also
  Status Clinical Trial Phase
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT02369445 - Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention N/A
Completed NCT01978210 - Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism N/A
Recruiting NCT06070675 - Comparison of a Paper and Automated Bladder Diary in Pediatric Patients N/A
Completed NCT01747343 - Toilet Training Toddlers and Preschoolers N/A
Recruiting NCT00437528 - Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity Phase 1
Recruiting NCT02699528 - The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder N/A
Withdrawn NCT01861145 - Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea Phase 4
Completed NCT04260646 - Alarm Treatment for Combined Enuresis and Daytime Urinary Incontinence in Children N/A
Completed NCT00270621 - Family Help Program: Nighttime Enuresis Treatment Program Phase 2
Completed NCT01367080 - A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg Phase 1
Completed NCT00226122 - The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal Phase 4
Completed NCT05190601 - Uroflowmetry in Children With Enuresis Nocturnal
Withdrawn NCT03478813 - Voiding School as a Treatment of Children's Day-time Incontinence or Enuresis N/A
Recruiting NCT03399877 - A Study on Accuracy Improvement of Repeated Measure Uroflowmetry- Electromyography N/A
Active, not recruiting NCT06185361 - Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. N/A
Completed NCT04280887 - MyPad - Intelligent Bladder Pre-void Alerting System N/A
Completed NCT00240812 - A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting Phase 2